Introduction: Tuberculosis (TB) due to infection of the Mycobacterium tuberculosis has become a concern since this disease has been suffered by most of the world's population and causes death in large numbers. The increasing number of TB patients has increased our vigilance to reduce the spread of this disease. One of the efforts to provide effective treatment for cases of infection by this bacterium is to determine the proper anti-tuberculosis drug. Methods: This study tested M. tuberculosis isolates against several tuberculosis drugs, such as isoniazid, quinolone (ofloxacin and moxifloxacin), kanamycin, capreomycin, bedaquiline, linezolid, and clofazimine in MGIT liquid medium. The isolates used were bacterial stock belonging to the Department of Microbiology, Medical Faculty, Universitas Indonesia. All isolates used had a resistance phenotype to the anti-tuberculosis drug rifampicin determined by the GeneXpert MTB/Rif method. Results: From all the isolates tested, the percentage of anti-tuberculosis resistance was as follows: low-dose isoniazid 70.4%, high-dose isoniazid 66.7%, ofloxacin 9.9%, low-dose moxifloxacin 9.9%, high-dose moxifloxacin 2.5%, and bedaquiline 5.1%. There was no resistance to linezolid and clofazimine among the tested isolates. This study also found that 57 isolates were multi-drug resistant (MDR) strains, six isolates were pre-extensively drug resistance (XDR), and one isolate was an XDR strain. Conclusion: This study presented an overview of the resistance profile of M. tuberculosis to several first-, second-line and new tuberculosis drugs in vitro. The results of this study can be used by stakeholders in the health sector to develop policies for better management of tuberculosis.
|Number of pages||6|
|Journal||Malaysian Journal of Medicine and Health Sciences|
|Publication status||Published - Sept 2022|
- Anti-tuberculosis drugs
- M. tuberculosis